There are 2137 resources available
754P - Ibrutinib (Ibr) in combination with paclitaxel (Pac) has activity in patients (Pts) with advanced urothelial carcinoma (aUC): Final analysis of a phase Ib/II study
Presenter: Daniel Castellano Gauna
Session: E-Poster Display
Resources:
Abstract
755P - Comparative clinical efficacy of neoadjuvant (NACT) versus adjuvant chemotherapy (ACT) in the treatment of locally advanced penile cancer (PeCa): A proportional meta-analysis of case series
Presenter: Kevin Gallagher
Session: E-Poster Display
Resources:
Abstract
756P - Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
757P - An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(Ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status
Presenter: Arash Rezazadeh
Session: E-Poster Display
Resources:
Abstract
758P - Assessment of prognostic and predictive value of FGFR alterations (FGFRa) in a real-world cohort of patients (pts) with high-risk pT1 non-muscle-invasive bladder cancer (NMIBC)
Presenter: Johannes Breyer
Session: E-Poster Display
Resources:
Abstract
759P - Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy
Presenter: Daniel Castellano Gauna
Session: E-Poster Display
Resources:
Abstract
760P - Platinum-based adjuvant chemotherapy in upper tract urothelial carcinomas (UTUCs): A change of paradigm? A meta-analysis of aggregate data
Presenter: Angela Dalia Ricci
Session: E-Poster Display
Resources:
Abstract
761P - Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
Presenter: Juan Rodriguez-Moreno
Session: E-Poster Display
Resources:
Abstract
762P - Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new sequential therapies in pathologically-nonresponders
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
763P - The influence of multidisciplinary team meetings on treatment decisions in muscle invasive bladder cancer: A nationwide study in the Netherlands
Presenter: Janneke Walraven
Session: E-Poster Display
Resources:
Abstract